Pamela Stephenson - Dec 27, 2022 Form 4/A - Amendment Insider Report for ALBIREO PHARMA, INC. (ALBO)

Role: Chief Commercial Officer
Signature: /s/ Jason Duncan, Attorney-in-fact
Stock symbol: ALBO
Transactions as of: Dec 27, 2022
Transactions value $: -$8,940
Form type: 4/A - Amendment
Date filed: 1/9/2023, 05:42 PM
Date Of Original Report: Dec 27, 2022
Previous filing: Oct 25, 2022
Next filing: Jan 27, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALBO	Common Stock	Sale	-$8.94K	-469	-1.04%	$19.06	44.6K	Dec 27, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2	Represents 18,374 shares of common stock and 26,257 restricted stock units.

Remarks:

This amended Form 4 is being filed solely to correct the numbers of shares disclosed in column 5 of Table I and footnote 3, as the reporting person did not acquire 547 shares of common stock under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan on May 31, 2022.